NCT04389671 - The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

February 20, 2022

Study Completion Date

February 20, 2022

Conditions

COVID-19Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Interventions

DRUG

Lucinactant

Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered

Trial Locations (11)

Duke University Medical Center, Durham

Augusta University Health, Augusta

University of Kentucky, Lexington

University California San Diego - Jacobs Medical Center, La Jolla

University of California San Diego - Medical Center, Hillcrest, San Diego

Tufts Medical Center, Boston

Brigham and Women's Hospital, Boston

Fundacion Sanatorio Güemes, Buenos Aires

Hospital Alemán, Buenos Aires

Hospital Italiano de Bueno Aires, Buenos Aires

CEMIC - Centro de Educacion Medica e Investigaciones Clinicals, Buenos Aires